Intermediate-, Long-acting, and Combination Insulins

The phrase "Intermediate-, Long-acting, and Combination Insulins" functions as a compendial and formulary classification category rather than a single distinct molecular class

It encompasses intermediate-acting insulins (such as NPH), long- or ultra-long-acting basal insulin analogs (such as glargine, detemir, and degludec), fixed-ratio premixed insulins, and combinations with non-insulin injectables

It encompasses intermediate-acting insulins (such as NPH), long- or ultra-long-acting basal insulin analogs (such as glargine, detemir, and degludec), fixed-ratio premixed insulins, and combinations with non-insulin injectables

It encompasses intermediate-acting insulins (such as NPH), long- or ultra-long-acting basal insulin analogs (such as glargine, detemir, and degludec), fixed-ratio premixed insulins, and combinations with non-insulin injectables

These agents mimic physiological basal pancreatic insulin secretion, stimulate cellular glucose uptake, and suppress hepatic gluconeogenesis to maintain glycemic control over extended periods or across both fasting and postprandial states Clinically, these formulations are primarily indicated for the management of type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes

These agents mimic physiological basal pancreatic insulin secretion, stimulate cellular glucose uptake, and suppress hepatic gluconeogenesis to maintain glycemic control over extended periods or across both fasting and postprandial states

These agents mimic physiological basal pancreatic insulin secretion, stimulate cellular glucose uptake, and suppress hepatic gluconeogenesis to maintain glycemic control over extended periods or across both fasting and postprandial states

Clinically, these formulations are primarily indicated for the management of type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes